From June 19th to 21st, the 22nd World Pharmaceutical Ingredients China Exhibition (CPHI China 2024) and the 17th World Pharmaceutical Machinery, Packaging Equipment and Materials China Exhibition (PMEC China 2024) were held at the Shanghai New International Expo Centre. CPHI & PMEC China are among Asia’s leading professional pharmaceutical industry exhibitions, and have become a large-scale global platform for pharmaceutical product trade, investment, and cooperation. Enzyme products once again graced the international stage of CPHI China, gathering with renowned domestic and international exhibitors, partners, experts, and scholars to jointly promote the vigorous development of the global raw materials industry.
1. Highlights
Enzyme Products made a strong comeback at this exhibition with its flagship product portfolio, covering three major areas: biomedicine, functional skincare, and nutrition and health. The products comprehensively showcased the diversified and innovative applications of “life molecules” green active raw materials in the health consumer market. The booth (W3G02) was bustling with activity and featured a constant stream of exciting events.
For the biopharmaceutical field, the enzyme products offer a comprehensive GLP-1RA solution, including semaglutide.( Semaglutide), TirzepatideThe company supplies key raw materials, intermediates, custom peptide fragments, and injection pens for GLP-1RA drugs, including semaglutide. Among these, semaglutide, synthesized using biotechnology, has successfully obtained FDA DMF (DMF number assigned: 039791) .
Based on the comprehensive strength of the “Green Bio-Intelligent Manufacturing Platform” for finished enzyme products, the company has achieved major technological breakthroughs in many fields such as novel gene editing technology, specific enzyme modification technology, strain modification technology, high-density fermentation technology, bio-conjugation technology, and the application of novel purification technologies . This has enabled the company to achieve a stable market supply of hundreds of kilograms of Smeglucopyritide raw materials, ensuring stable and controllable product quality and significantly improving its economic efficiency.
2. Regarding finished enzyme products
Enzyme Products is committed to becoming a global leader in next-generation green active ingredients. Utilizing next-generation synthetic biology technology, the company focuses on the green production of active ingredients such as peptides, proteins, sugars, and nucleic acids. Leveraging over 20 years of research and industry experience accumulated by its founding team, the company has established a leading multidisciplinary technology platform in China. It has now achieved mass production of dozens of green active ingredients, including Smegglutinin, NMN, S -Bosein, and blue copper peptide , providing high-quality green active ingredients to nearly a thousand well-known companies in the fields of biomedicine, functional skincare, and nutritional health.
After several years of rapid development, the company has achieved a leading position among domestic enterprises in terms of R&D investment, scale, and output. It has applied for more than 100 invention patents and has won more than ten national and local titles, including National Specialized and Innovative Small Giant, National High-tech Enterprise, Shenzhen Specialized and Innovative Small and Medium Enterprise, Shenzhen Potential Unicorn Enterprise, Shenzhen Postdoctoral Innovation Practice Base, Shenzhen Top 30 Medical and Health Innovation Team, Zhuhai Innovation and Entrepreneurship Team, and Gansu Specialized and Innovative Small and Medium Enterprise. In 2022, it was selected as one of Shenzhen’s Top 100 High-Growth Enterprises (first among unlisted biotech companies), and in 2023, it was selected as a Harvard Business Review High-Energy Innovation Team.